viO HealthTech’s vision is to provide a targeted personalised approach to the major women’s health issues of conception, Polycystic Ovarian Syndrome (“PCOS”), diminished ovarian reserve, miscarriage risk, pregnancy complications and menopause.
The founding team built the company’s first product, OvuSense, from a deep personal understanding of the heartache and joy of the trying to conceive journey, and we continue to be passionately driven by the real world experiences of couples and women throughout their reproductive life from puberty to menopause.
We currently offer a family of three monitoring products approved for all major worldwide markets:
OvuFirst™ is a completely unique patented sensor technology designed to measure continuous skin temperature during sleep giving women the best minimally invasive method of understanding of the fluctuations in progesterone which occur during their cycle. Worn on the underside of the arm or wrist, OvuFirst takes readings of skin temperature every 5 minutes overnight, the data are downloaded to the free OvuSense® App every morning, and the App provides updates to fertility status throughout the reproductive cycle. Designed for women that have regular cycles and for further monitoring when not actively trying to conceive, OvuFirst is clinically proven to be the most accurate skin-worn sensor on the market. [a], [b]
OvuCore™ is a completely unique patented sensor technology designed to measure continuous Core Body Temperature (cCBT) in the vagina during sleep, giving women the best possible understanding of the fluctuations in progesterone which occur during their cycle, helping not only with conception but with screening for health issues and monitoring treatment. OvuCore takes readings of cCBT every 5 minutes overnight, the data are downloaded to the free OvuSense® App every morning, and the App provides updates to fertility status throughout the reproductive cycle. Designed for women If that have been trying to conceive for a while or that know they may have an issue like Polycystic Ovarian Syndrome (PCOS), OvuCore enables the OvuSense App to predict the onset of ovulation up to 24 hours in advance with a positive predictive value of 96% [c], [d], provides 99% accuracy for detection of the exact date of ovulation [b], [d], and confirms the absence of ovulation – all in realtime. No other method of cycle monitoring in the clinic or home offers these features.
OvuSense® Pro allows an OvuSense user and their doctor to remotely access detailed cycle information through an online portal. It provides unique key analysis about cycle patterns to help medical professionals to know whether they need to carry out further tests, to time tests like blood progesterone and ultrasound, and to understand whether medications, treatment or dietary change are having the desired effect. This information is vital in helping couples gain confidence in their treatment and conceive more quickly. OvuSense Pro is based on novel clinical publications published from an ongoing epidemiological study [e].
viO HealthTech is driven by the emergence of new medical understanding of women’s health. We’ve invested heavily in patenting our unique technology [f] and will continue to use our relationship with specialists in the field this provide solutions for improving the chance for couples to conceive, and for women to manage key aspects of their health when they are not actively trying to conceive.
=====
[a] Internal vio HealthTech (formerly Fertility Focus) side by side study of OvuFirst and OvuCore Sensors (2021), documented as a class II medical device in the notified body reviewed CE Certificate Technical File.
[b] The accuracy measures how many positive and absent ovulations the device confirms correctly.
[c] The positive predictive value measures how many of the real time predicted ovulations OvuSense gets right.
[d] The accuracy of ovulation confirmation by OvuSense is based on the data set originally published at the 2013 ASRM meeting as a quality index: Papaioannou S, Aslam M (2013), and developed in the key publication outlining the accuracy and positive predictive value of advance prediction of ovulation shown at the 2014 ESHRE meeting: Papaioannou S, Delkos D, Pardey J (2014).
[e] Further publications have identified:
– the wide spread of day of ovulation in OvuSense user cycles:
Hurst BS, Citron C (2020) Normalised Ovulation Timing in Population using Core Body Temperature Monitoring to conceive S-194 Society for Reproductive Investigation, 2020 Annual Meeting.
– the association of atypical cycle patterns displayed by the OvuSense Pro product and ovulatory issues:
Karoshi M, Hurst B (2020) Atypical Temperature Patterns as an Aid to Identify Infertility Issues and Miscarriage Risk. P-628 European Society of Human Reproduction and Embryology 36th Annual Meeting.
– the atypical cycle patterns which led to the development of the OvuSense Pro product:
Hurst BS, Karoshi M (2020) Atypical Core Body Temperature patterns and the wider implications for conditions related to pregnancy, infertility, and miscarriage risk P-833 American Society for Reproductive Medicine 76th Annual conference. Poster; Fertility and Sterility – September 2020 Volume 114, Issue 3, Supplement, Pages e446–e447 |
Hurst BS, Pirrie A (2019) Atypical vaginal temperature patterns may identify subtle not yet recognised causes of infertility P-345 American Society for Reproductive Medicine 75th Annual conference.;, Fertility and Sterility – September 2019 Volume 112, Issue 3, Supplement, Pages e244–e245;
– the background science for OvuSense:
Papaioannou S, Aslam M (2012) Ovulation assessment by vaginal temperature analysis (Ovusense Fertility Monitoring System) in comparison to oral temperature recording. American Society for Reproductive Medicine 68th Annual conference.; Papaioannou S, Aslam M (2012) Ovulation Assessment and Fertile Period Prediction by Portable Computerised Vaginal Temperature Analysis – The OvuSense Advanced Fertility Monitoring System. European Society of Human Reproduction and Embryology 28th Annual Conference.
OvuSense is backed by a significant number of patents. Very few other products have this degree of proof of novel technology:
[f] US Patents: US8684944, US8496597, US9155522, US9155523, US20190110692; European patents: EP1485690, EP2061380, DE20 2014 011 334, DE20 2014 011 335; Chinese patent: CN1650154